News Date: Monday, December 5, 2022 - 10:00
Zoom link : https://pennmedicine.zoom.us/j/9821888321 Please share the link with interested colleagues
Dr. Matthew Johnson is at the leading edge of the surging psychedelic research domain, having begun his work in 2004, when he joined Dr. Roland Griffiths and the team at Johns Hopkins. Dr. Johnson and his team are responsible for the 2008 psychedelic safety guidelines that encouraged research by others, and laid the foundation for the ongoing therapeutic work with psychedelics. He and his colleagues have led rigorous studies on the impact of psychedelic treatment for tobacco use disorder, and for cancer distress, with ongoing studies in opioid use disorder and PTSD. Though these treatment studies use psilocybin (he has led or supervised hundreds of clinical sessions), he has also conducted research with salvinorum A, and with MDMA (‘ecstasy’). Given his pioneering research, Dr. Johnson is a sought-after speaker, and has been interviewed widely in the media (links below). As you will hear today, he is a natural and effective speaker and teacher. As a final note -- addition to his work with psychedelics, Dr. Johnson also published extensively in behavioral pharmacology and decision-making, including the impact of cocaine on sexual decision-making in humans. For today’s talk, he will focus on the promise of psychedelic treatment for tobacco use disorder – a challenging disorder that takes more lives each year than all the illicit drugs combined.